On May, 9 Analysts See $-1.94 EPS for BeiGene, Ltd. (BGNE)

April 17, 2018 - By Mary Markley

BeiGene, Ltd. (NASDAQ:BGNE) Corporate Logo

On May, 9 is expected BeiGene, Ltd. (NASDAQ:BGNE)’s earnings report, according to Faxor. Analysts predict $-1.94 EPS. That’s $0.67 down or 52.76 % from 2017’s earnings of $-1.27. After $-2.19 EPS was announced last quarter, analysts now see EPS growth of -11.42 % for BeiGene, Ltd.. BGNE reached $166.62 on during the last trading session after $1.6 change.BeiGene, Ltd. has volume of 179,924 shares. Since April 17, 2017 BGNE has risen 354.57% and is uptrending. The stock outperformed the S&P500 by 343.02%.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer.The firm is valued at $8.87 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations.Currently it has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

BeiGene, Ltd. (NASDAQ:BGNE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.